bcdiabetes.ca
Patient Care + Research + Clinical Trials

Dr. Tom Elliott MBBS, FRCPC
Medical Director

400 - 210 W Broadway
Vancouver, BC
V5Y 3W2 Canada

phone: 604.683.3734
fax: 604.628.3821
email: moa@bcdiabetes.ca

OBTAIN - nanobody Rx in newly diagnosed T1 age 12-21

Note: recruitment was halted by the sponsor 2026-01-13 for business reasons

Study location BCDiabetes: 400 - 210 West Broadway, Vancouver V5Y 3W2

Principal Investigators Drs. Tom Elliott, Dale Clayton and David Lee

Study coordinator & primary contact Dr. Hector Com P: 604-628-7253 x 7012: hcom@bcdiabetes.ca

Summary: OBTAIN (ACT 18368) is a phase 2a double-blind, placebo controlled RCT, parallel group, multicenter study testing efficacy and safety of SAR442970, a dual anti-TNF-α and anti-OX40L NANOBODY® molecule in newly diagnosed T1DM patients. This has previously been given to 125 human subjects - 67 in Phase 1 and 58 unblinded from previous Phase 2 study with no significant risk attributable to the intervention.
Odds of receiving the new molecule : 3:1 (SAR442970 or placebo)

Hypothesis: The synergistic effect of blocking both pathways, TNF-α and OX40L is expected to stop the progression of the disease and preserve pancreatic β-cell function in patients with newly diagnosed type 1 diabetes on insulin therapy

Eligible Participants include:

- 12-21 yrs of age (Part B) expected to start 2026-03-01
- Newly diagnosed T1DM within 90 days of first insulin injection
- Positive to at least 1 autoAb (i.e. GAD65; IA-2, ZnT8), OR to insulin autoAb (if obtained within 10 days of first insulin injection).
- C peptide ≥ 0.2 nmol/L (by MMTT)

Treatment course and duration:

The study consists of 2 sequential parts, Part A for ages 18-35 (completed 2025-10-01) and Part B for ages 12-18, testing safety of SAR442970.
Once the participants' general health status and eligibility is confirmed at the Screening visit, the intervention will consist of subcutaneous injections being given every two weeks for 12 months followed by a 6 months follow-up period. Schedule of clinic visits would be as shown below:

Treatment period clinic visits							Follow-up visits	
Day 1 *	**Wk 1**	**Wk 4**	**Wk 12 ***	**Wk 26 ***	**Wk 38 ***	**Wk 52 ***	**Wk 64**	**Wk 78 ***

Visits marked with * include a 2-hr MMTT

Study documents:

Informed Consent Form
Protocol available upon request

Short url: https://bit.ly/OBTAINT1D